C. Csajka

Discipline

Psychologie (6) Sociologie (1) Sciences de l'information et de la communication (1) Economies et finances (1) Anthropologie biologique (1)

Type de document

Articles (45) Recensions (7) Colloques et conférences (7)

Co-auteur

Date

Source

Mot-clé

Patients (33) Patients (32) Treatment (28) Population (27) Population (26) modèle (23) Example (23) Pharmacokinetics (23) pharmacocinétique (22) Pharmacokinetics (22) Human beings (19) exposition (18) Models (18) dosage (17) thérapie (16) Therapeutics (16) plasma (16) analyse (15) dose (15) Older people (15) Analysis (15) abords (agglomération) (14) Drug monitoring (14) cohorte (14) Management (13) Impact (13) Drugs (12) Absorption (12) risque (11) surveillance (11)

Documents écrit par C. Csajka (52) | parle de C. Csajka (0)

Apixaban and rivaroxaban's physiologically-based pharmacokinetic model validation in hospitalized patients: A first step for larger use of a priori modeling approach at bed side.
J. Terrier et al.
Population pharmacokinetics of apixaban in a real-life hospitalized population from the OptimAT study.
F. Gaspar et al.
Predicting delirium in older non-intensive care unit inpatients: development and validation of the DELIrium risK Tool (DELIKT).
A.E. Schulthess-Lisibach et al.
Dementia prevention in memory clinics: recommendations from the European task force for brain health services.
G.B. Frisoni et al.
Adherence to the CDK 4/6 Inhibitor Palbociclib and Omission of Dose Management Supported by Pharmacometric Modelling as Part of the OpTAT Study.
C. Bandiera et al. (3 janv. 2023)
From personalized to precision medicine in oncology: A model-based dosing approach to optimize achievement of imatinib target exposure.
S. Goutelle et al. (2023)
Phage therapy for pulmonary infections: lessons from clinical experiences and key considerations.
G. Mitropoulou et al. (31 déc. 2022)
Population pharmacokinetic analyses of regorafenib and capecitabine in patients with locally advanced rectal cancer (SAKK 41/16 RECAP).
E. Schmulenson et al.
Phagothérapie pour traiter les infections respiratoires [Phage therapy for respiratory infections]
G. Mitropoulou et al. (16 nov. 2022)
Implementation and Cross-Validation of a Pharmacokinetic Model for Precision Dosing of Busulfan in Hematopoietic Stem Cell Transplanted Children.
S. Goutelle et al. (1 oct. 2022)
Dosing strategies of imipenem in neonates based on pharmacometric modelling and simulation.
K. Dao et al. (2 févr. 2022)
Medication Adherence Evaluated Through Electronic Monitors During the 2020 COVID-19 Pandemic Lockdown in Switzerland: A Longitudinal Analysis.
C. Bandiera et al. (2022)
Ability to detect potentially inappropriate prescribing in older patients: comparative analysis between PIM-Check and STOPP/STARTv2.
A. Farhat et al.
Protocols for cognitive enhancement. A user manual for Brain Health Services-part 5 of 6.
A. Brioschi Guevara et al. (11 oct. 2021)
Cross-cultural adaptation and psychometric validation of the revised Patients' Attitudes Towards Deprescribing (rPATD) questionnaire in French.
B. Roux et al.
Population pharmacokinetic modelling to quantify the magnitude of drug-drug interactions between amlodipine and antiretroviral drugs.
P. Courlet et al.
Pharmacokinetic/Pharmacodynamic Modelling to Describe the Cholesterol Lowering Effect of Rosuvastatin in People Living with HIV.
S. Alves Saldanha et al.
Quality of anticholinergic burden scales and their impact on clinical outcomes: a systematic review.
A. Lisibach et al.
Impact of Pharmaceutical Interventions in Hospitalized Patients: A Comparative Study Between Clinical Pharmacists and an Explicit Criteria-Based Tool.
A. Farhat et al. (2021)
Validation and clinical application of a multiplex high performance liquid chromatography - tandem mass spectrometry assay for the monitoring of plasma concentrations of 12 antibiotics in patients with severe bacterial infections.
L.A. Decosterd et al. (10 nov. 2020)
Enquête « RTO-COVID-19 » : nos soins, nos actions, leurs effets
B. Graz et al. (26 août 2020)
Influence of Drug-Drug Interactions on the Pharmacokinetics of Atorvastatin and Its Major Active Metabolite ortho-OH-Atorvastatin in Aging People Living with HIV.
P. Courlet et al.
Development and validation of a multiplex UHPLC-MS/MS assay with stable isotopic internal standards for the monitoring of the plasma concentrations of the antiretroviral drugs bictegravir, cabotegravir, doravirine, and rilpivirine in people living with HIV.
P. Courlet et al.
Population Pharmacokinetics/Pharmacodynamics of Dabrafenib Plus Trametinib in Patients with BRAF-Mutated Metastatic Melanoma.
D. Balakirouchenane et al. (9 avr. 2020)
Optimisation of vancomycin exposure in neonates based on the best level of evidence.
K. Dao et al.

next